212 related articles for article (PubMed ID: 20863376)
1. Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and casein kinase II inhibition as a potential treatment option.
Willems SM; Schrage YM; Bruijn IH; Szuhai K; Hogendoorn PC; Bovée JV
Mol Cancer; 2010 Sep; 9():257. PubMed ID: 20863376
[TBL] [Abstract][Full Text] [Related]
2. FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma.
Trautmann M; Menzel J; Bertling C; Cyra M; Isfort I; Steinestel K; Elges S; Grünewald I; Altvater B; Rossig C; Fröhling S; Hafner S; Simmet T; Åman P; Wardelmann E; Huss S; Hartmann W
Clin Cancer Res; 2017 Oct; 23(20):6227-6238. PubMed ID: 28637688
[No Abstract] [Full Text] [Related]
3. Nuclear expression of FLT1 and its ligand PGF in FUS-DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine signaling loop.
Andersson MK; Göransson M; Olofsson A; Andersson C; Aman P
BMC Cancer; 2010 Jun; 10():249. PubMed ID: 20515481
[TBL] [Abstract][Full Text] [Related]
4. The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ.
Göransson M; Andersson MK; Forni C; Ståhlberg A; Andersson C; Olofsson A; Mantovani R; Aman P
Oncogene; 2009 Jan; 28(2):270-8. PubMed ID: 18850010
[TBL] [Abstract][Full Text] [Related]
5. Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment.
Schrage YM; Briaire-de Bruijn IH; de Miranda NF; van Oosterwijk J; Taminiau AH; van Wezel T; Hogendoorn PC; Bovée JV
Cancer Res; 2009 Aug; 69(15):6216-22. PubMed ID: 19602594
[TBL] [Abstract][Full Text] [Related]
6. SRC inhibition represents a potential therapeutic strategy in liposarcoma.
Sievers E; Trautmann M; Kindler D; Huss S; Gruenewald I; Dirksen U; Renner M; Mechtersheimer G; Pedeutour F; Åman P; Nishio J; Schildhaus HU; Kirfel J; Schirmacher P; Wardelmann E; Buettner R; Hartmann W
Int J Cancer; 2015 Dec; 137(11):2578-88. PubMed ID: 26084847
[TBL] [Abstract][Full Text] [Related]
7. Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression.
Göransson M; Elias E; Ståhlberg A; Olofsson A; Andersson C; Aman P
Int J Cancer; 2005 Jul; 115(4):556-60. PubMed ID: 15688424
[TBL] [Abstract][Full Text] [Related]
8. FUS-CHOP Promotes Invasion in Myxoid Liposarcoma through a SRC/FAK/RHO/ROCK-Dependent Pathway.
Tornin J; Hermida-Prado F; Padda RS; Gonzalez MV; Alvarez-Fernandez C; Rey V; Martinez-Cruzado L; Estupiñan O; Menendez ST; Fernandez-Nevado L; Astudillo A; Rodrigo JP; Lucien F; Kim Y; Leong HS; Garcia-Pedrero JM; Rodriguez R
Neoplasia; 2018 Jan; 20(1):44-56. PubMed ID: 29190494
[TBL] [Abstract][Full Text] [Related]
9. Detection of TLS/FUS-CHOP fusion transcripts in myxoid and round cell liposarcomas by nested reverse transcription-polymerase chain reaction using archival paraffin-embedded tissues.
Hisaoka M; Tsuji S; Morimitsu Y; Hashimoto H; Shimajiri S; Komiya S; Ushijima M
Diagn Mol Pathol; 1998 Apr; 7(2):96-101. PubMed ID: 9785008
[TBL] [Abstract][Full Text] [Related]
10. Myxoid liposarcoma-associated EWSR1-DDIT3 selectively represses osteoblastic and chondrocytic transcription in multipotent mesenchymal cells.
Suzuki K; Matsui Y; Higashimoto M; Kawaguchi Y; Seki S; Motomura H; Hori T; Yahara Y; Kanamori M; Kimura T
PLoS One; 2012; 7(5):e36682. PubMed ID: 22570737
[TBL] [Abstract][Full Text] [Related]
11. The FUS-DDIT3 Interactome in Myxoid Liposarcoma.
Yu JSE; Colborne S; Hughes CS; Morin GB; Nielsen TO
Neoplasia; 2019 Aug; 21(8):740-751. PubMed ID: 31220736
[TBL] [Abstract][Full Text] [Related]
12. FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro.
Künstlinger H; Fassunke J; Schildhaus HU; Brors B; Heydt C; Ihle MA; Mechtersheimer G; Wardelmann E; Büttner R; Merkelbach-Bruse S
Oncotarget; 2015 Aug; 6(24):20215-30. PubMed ID: 26036639
[TBL] [Abstract][Full Text] [Related]
13. Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation.
de Graaff MA; Yu JS; Beird HC; Ingram DR; Nguyen T; Juehui Liu J; Bolshakov S; Szuhai K; Åman P; Torres KE; Lev D; Nielsen TO; Bovée JV; Lazar AJ; Somaiah N
Lab Invest; 2016 Aug; 96(8):885-94. PubMed ID: 27270875
[TBL] [Abstract][Full Text] [Related]
14. Role of FUS-CHOP in Myxoid Liposarcoma via miR-486/CDK4 Axis.
Wu H; Xia L; Xu H
Biochem Genet; 2022 Jun; 60(3):1095-1106. PubMed ID: 34792704
[TBL] [Abstract][Full Text] [Related]
15. Establishment and characterization of NCC-MLPS1-C1: a novel patient-derived cell line of myxoid liposarcoma.
Noguchi R; Yoshimatsu Y; Sei A; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
Hum Cell; 2021 Mar; 34(2):667-674. PubMed ID: 33146842
[TBL] [Abstract][Full Text] [Related]
16. HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo.
Safavi S; Järnum S; Vannas C; Udhane S; Jonasson E; Tomic TT; Grundevik P; Fagman H; Hansson M; Kalender Z; Jauhiainen A; Dolatabadi S; Stratford EW; Myklebost O; Eriksson M; Stenman G; Schneider-Stock R; Ståhlberg A; Åman P
Oncotarget; 2016 Jan; 7(1):433-45. PubMed ID: 26595521
[TBL] [Abstract][Full Text] [Related]
17. Paratesticular myxoid/round cell liposarcoma harboring type 3 DDIT3-FUS fusion gene: report of a very rare case.
Zozumi M; Nakai M; Matsuda I; Hao H; Tsukamoto Y; Shiraishi Y; Nojima M; Yamamoto S; Hirota S
Pathol Res Pract; 2013 Feb; 209(2):124-7. PubMed ID: 23276404
[TBL] [Abstract][Full Text] [Related]
18. Identification of inhibitors regulating cell proliferation and FUS-DDIT3 expression in myxoid liposarcoma using combined DNA, mRNA, and protein analyses.
Svec D; Dolatabadi S; Thomsen C; Cordes N; Shannon M; Fitzpatrick P; Landberg G; Åman P; Ståhlberg A
Lab Invest; 2018 Jul; 98(7):957-967. PubMed ID: 29588491
[TBL] [Abstract][Full Text] [Related]
19. The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells.
Engström K; Willén H; Kåbjörn-Gustafsson C; Andersson C; Olsson M; Göransson M; Järnum S; Olofsson A; Warnhammar E; Aman P
Am J Pathol; 2006 May; 168(5):1642-53. PubMed ID: 16651630
[TBL] [Abstract][Full Text] [Related]
20. DDIT3 gene break-apart as a molecular marker for diagnosis of myxoid liposarcoma--assay validation and clinical experience.
Narendra S; Valente A; Tull J; Zhang S
Diagn Mol Pathol; 2011 Dec; 20(4):218-24. PubMed ID: 22089349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
